Tumor’s DIY Blood Vessels

Tumor cell vascular mimicry: Novel targeting opportunity in melanoma

Phase I dose escalation study of CVM-1118, a novel anti-vascular mimicry agent, in patients with advanced cancers

Vasculogenic Mimicry: Become an Endothelial Cell “But Not So Much”

CVM-1118 (foslinanib), A 2-phenyl-4-quinolone derivative, promotes apoptosis and inhibits vasculogenic mimicry via targeting TRAP1

CVM-1118: A potent oral anti-vasculogenic mimicry (VM) agent in patients with advanced neuroendocrine tumors (NETs)—A phase IIa study

CVM-1118: An oral anti-vasculogenic mimicry (VM) agent in combination with Nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC)—a Phase IIa study

An oral anti-vasculogenic mimicry (VM) agent in combination with Nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC)—a Phase IIa study

CVM-005: Phase IIa study of CVM-1118, a novel oral anti-vasculogenic mimicry (VM) agent, in advanced neuroendocrine tumors (NET) after progression on prior therapy

CVM-005: A multicenter, single-arm, phase IIa study of CVM-1118, a novel oral anti-vasculogenic mimicry (VM) agent, in patients with treatment-refractory advanced neuroendocrine tumors (NET)

Comparison of Gpx-3 Protein Expression and Enzyme Bioactivity in Normal Subjects and Patients with Sepsis

Epidemiology of sepsis in Taiwan

Costs and length of sepsis-related hospitalizations in Taiwan

Effects of high-dose selenium on mortality of sepsis and septic shock patients with severe selenium deficiency in Taiwan